In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma

被引:0
|
作者
Abas Sezer
Lejla Mahmutović
Betül Akçeşme
机构
[1] International University of Sarajevo,Department of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences
[2] University of Health Sciences,Department of Basic Medical Sciences, Division of Medical Biology
来源
关键词
Non-Hodgkin lymphoma; NF-ĸB signaling pathway; CBM complex; MALT1; Molecular docking; Polyphenols;
D O I
暂无
中图分类号
学科分类号
摘要
Non-Hodgkin lymphoma (NHL) is one of the most common cancer types. Deregulated signaling pathways can trigger certain NHL subtypes, including Diffuse Large B-cell lymphoma. NF-ĸB signaling pathway, which is responsible for the proliferation, growth, and survival of cells, has an essential role in lymphoma development. Although different signals control NF-ĸB activation in various lymphoid malignancies, the characteristic one is the CARD11-BCL10-MALT1 (CBM) complex. The CBM complex is responsible for the initiation of adaptive immune response. Our study is focused on the molecular docking of ten polyphenols as potential CARD11-BCL10-MALT1 complex inhibitors, essentially through MALT1 inhibition. Molecular docking was performed by Auto Dock Tools and AutoDock Vina tool, while SwissADME was used for drug-likeness and absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis of the ligands. Out of 66 ligands that were used in this study, we selected and visualized five. Selection criteria were based on the binding energy score and position of the ligands on the used protein. 2D and 3D visualizations showed interactions of ligands with the protein. Five ligands are considered potential inhibitors of MALT1, thus affecting NF-ĸB signaling pathway. However, additional in vivo and in vitro studies are required to confirm their mechanism of inhibition.
引用
收藏
相关论文
共 50 条
  • [41] HEPATIC HUMORAL AND MORPHOLOGIC STUDY IN NON-HODGKIN LYMPHOMA
    GARAY, GE
    ZEILICOFF, R
    RICHARD, LA
    BALLETTI, N
    KOCH, O
    DOMECQ, P
    BRUSH, E
    PAVLOVSKY, S
    MEDICINA-BUENOS AIRES, 1981, 41 : 49 - 56
  • [42] Intestinal non-Hodgkin's lymphoma: A multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma
    Daum, S
    Ullrich, R
    Heise, W
    Dederke, B
    Foss, HD
    Stein, H
    Thiel, E
    Zeitz, M
    Riecken, EO
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2740 - 2746
  • [43] Renal synchronous carcinoma of clear cells with non-hodgkin lymphoma of phenotype b of Type MALT
    Contreras-Ibanez, J. A.
    Diaz-Gomez, L.
    Muriel-Cueto, P.
    ACTAS UROLOGICAS ESPANOLAS, 2010, 34 (09): : 818 - 819
  • [44] Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them
    Savage, Kerry J.
    Steidl, Christian
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (11) : 1007 - 1009
  • [45] Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Muller, Horst
    Elger, Leonard
    Goergen, Helen
    Fuchs, Michael
    Kreissl, Stefanie
    Boll, Boris
    Diehl, Volker
    von Tresckow, Bastian
    Borchmann, Peter
    Engert, Andreas
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (03) : 515 - 519
  • [46] Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study
    Purdue, Mark P.
    Lan, Qing
    Kricker, Anne
    Grulich, Andrew E.
    Vajdic, Claire M.
    Turner, Jennifer
    Whitby, Denise
    Chanock, Stephen
    Rothman, Nathaniel
    Armstrong, Bruce K.
    CARCINOGENESIS, 2007, 28 (03) : 704 - 712
  • [47] Human Pegivirus: Pathogenic potential and non-Hodgkin lymphoma development risk
    Arroyave-Ospina, Johanna C.
    Caicedo, Maria Fernanda
    Navas, Marla Cristina
    Cortes-Mancera, Fabian M.
    REVISTA CHILENA DE INFECTOLOGIA, 2018, 35 (02): : 164 - 175
  • [48] CD99 Is a Potential Therapeutic Target in Non-Hodgkin Lymphoma
    Tavakkoli, Montreh
    Lee, Dong
    Durham, Benjamin
    Feldstein, Julie
    Park, Christopher
    LABORATORY INVESTIGATION, 2015, 95 : 381A - 381A
  • [49] CD99 Is a Potential Therapeutic Target in Non-Hodgkin Lymphoma
    Tavakkoli, Montreh
    Lee, Dong
    Durham, Benjamin
    Feldstein, Julie
    Park, Christopher
    MODERN PATHOLOGY, 2015, 28 : 381A - 381A
  • [50] Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma
    Fang X.
    Zhou X.
    Wang X.
    Biomarker Research, 1 (1)